Login / Signup
Your account is not claimed yet. You can
sign up with ORCID
to claim your account.
Gen-Sheng Feng
ORCID
Publication Activity (10 Years)
Years Active: 2020-2023
Publications (10 Years): 3
Top Topics
Palliative Care
Phase Iii
Squamous Cell
Advanced Cancer
Top Venues
FASEB bioAdvances
Hepatology (Baltimore, Md.)
eLife
</>
This page only lists publications with an associated author ORCID identifier.
Publications
</>
Kota Kaneko
,
Yan Liang
,
Qing Liu
,
Shuo Zhang
,
Alexander Scheiter
,
Dan Song
,
Gen-Sheng Feng
Identification of CD133 + intercellsomes in intercellular communication to offset intracellular signal deficit.
eLife
12 (2023)
Jacey J Liu
,
Bing Xin
,
Li Du
,
Lydia Chen
,
Yanyan Long
,
Gen-Sheng Feng
Pharmaceutical SH2 domain-containing protein tyrosine phosphatase 2 inhibition suppresses primary and metastasized liver tumors by provoking hepatic innate immunity.
Hepatology (Baltimore, Md.)
(2022)
Shoib Sarwar Siddiqui
,
Michael Vaill
,
Raymond Do
,
Naazneen Khan
,
Andrea L Verhagen
,
Wu Zhang
,
Heinz-Josef Lenz
,
Teresa L Johnson-Pais
,
Robin J Leach
,
Gary E Fraser
,
Charles Wang
,
Gen-Sheng Feng
,
Nissi Varki
,
Ajit Varki
Human-specific polymorphic pseudogenization of SIGLEC12 protects against advanced cancer progression.
FASEB bioAdvances
3 (2) (2020)